| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
118.41(B) |
| Last
Volume: |
2,362,590 |
Avg
Vol: |
1,608,800 |
| 52
Week Range: |
$323.62 - $456.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
27,952 |
149,290 |
264,317 |
624,786 |
| Total Sell Value |
$12,512,803 |
$62,732,519 |
$104,276,665 |
$212,070,018 |
| Total People Sold |
8 |
12 |
14 |
18 |
| Total Sell Transactions |
9 |
42 |
65 |
132 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2021-02-10 |
4 |
D |
$214.16 |
$518,481 |
D/D |
(2,421) |
68,002 |
|
- |
|
| Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
• – – |
2021-02-10 |
4 |
D |
$214.16 |
$263,417 |
D/D |
(1,230) |
34,468 |
|
- |
|
| Bozic Carmen |
EVP and CMO |
• – – |
2021-02-10 |
4 |
D |
$214.16 |
$506,917 |
D/D |
(2,367) |
33,575 |
|
- |
|
| Parini Michael |
EVP, Chief Adm, Leg & BD Off |
• – – |
2021-02-05 |
4 |
AS |
$215.00 |
$414,950 |
D/D |
(1,930) |
57,227 |
|
-13% |
|
| Parini Michael |
EVP, Chief Adm, Leg & BD Off |
• – – |
2021-02-05 |
4 |
OE |
$86.52 |
$166,984 |
D/D |
1,930 |
59,157 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic TherapiesO |
• – – |
2021-02-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,175 |
|
-10% |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2021-02-03 |
4 |
AS |
$211.22 |
$332,146 |
D/D |
(1,554) |
69,957 |
|
-10% |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2021-02-03 |
4 |
OE |
$86.52 |
$134,452 |
D/D |
1,554 |
71,511 |
|
- |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
34,778 |
69,957 |
|
- |
|
| Wagner Charles F Jr |
EVP & Chief Financial Officer |
• – – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
21,951 |
38,138 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
32,077 |
70,423 |
|
- |
|
| Silva Paul M |
SVP & Chief Accounting Officer |
• – – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
11,080 |
26,012 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
32,453 |
61,355 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
20,719 |
41,894 |
|
- |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2021-02-03 |
4 |
D |
$215.03 |
$1,849,043 |
D/D |
(8,599) |
77,600 |
|
- |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
83,888 |
86,199 |
|
- |
|
| Parini Michael |
EVP, Chief Adm, Leg & BD Off |
• – – |
2021-02-03 |
4 |
AS |
$215.52 |
$86,624 |
D/D |
(400) |
57,227 |
|
-10% |
|
| Parini Michael |
EVP, Chief Adm, Leg & BD Off |
• – – |
2021-02-03 |
4 |
OE |
$86.52 |
$34,608 |
D/D |
400 |
57,627 |
|
- |
|
| Parini Michael |
EVP, Chief Adm, Leg & BD Off |
• – – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
30,389 |
57,227 |
|
- |
|
| Kewalramani Reshma |
CEO & President |
• • – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
44,935 |
71,583 |
|
- |
|
| Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
• – – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
22,960 |
35,698 |
|
- |
|
| Bozic Carmen |
EVP and CMO |
• – – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
21,951 |
35,942 |
|
- |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2020-12-08 |
4 |
GD |
$0.00 |
$0 |
I/I |
3,391 |
7,368 |
|
- |
|
| Arbuckle Stuart A |
EVP, Chief Commercial Officer |
• – – |
2020-11-16 |
4 |
AS |
$222.47 |
$1,565 |
D/D |
(7) |
35,179 |
|
-3% |
|
| Parini Michael |
EVP, Chief Adm, Leg & BD Off |
• – – |
2020-11-16 |
4 |
AS |
$222.52 |
$20,341 |
D/D |
(91) |
26,838 |
|
-3% |
|
1777 Records found
|
|
Page 19 of 72 |
|
|
12.29 (2.77%) 
